+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Phosphodiesterase"

From
Global Phosphodiesterase (PDE) Inhibitors Market 2024-2028 - Product Thumbnail Image

Global Phosphodiesterase (PDE) Inhibitors Market 2024-2028

  • Report
  • December 2023
  • 165 Pages
  • Global
From
From
Drugs for Erectile Dysfunction Global Market Report 2024 - Product Thumbnail Image

Drugs for Erectile Dysfunction Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Drugs For Benign Prostatic hypertrophy Global Market Report 2024 - Product Thumbnail Image

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
From
Global Pulmonary Arterial Hypertension Drugs Market 2023-2027 - Product Thumbnail Image

Global Pulmonary Arterial Hypertension Drugs Market 2023-2027

  • Report
  • March 2023
  • 172 Pages
  • Global
From
From
From
From
From
Loading Indicator

Phosphodiesterase (PDE) is a class of enzymes that catalyze the hydrolysis of phosphodiester bonds. They are involved in a variety of physiological processes, including signal transduction, metabolism, and cell division. In the pharmaceutical industry, PDE inhibitors are used to treat a variety of conditions, including erectile dysfunction, pulmonary hypertension, and asthma. PDE inhibitors work by blocking the action of the enzyme, allowing for increased levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This can lead to increased blood flow, relaxation of smooth muscle, and improved airway function. Some companies in the PDE market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more